Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Niels Schaft"'
Autor:
Carola Berking, Gerold Schuler, Olaf Wolkenhauer, Annelies W Turksma, Heiko Bruns, Julio Vera, Martin Eberhardt, Manuel Wiesinger, Beatrice Schuler-Thurner, Cindy Flamann, Markus Vincent Heppt, Shailendra Gupta, Christopher Lischer, Johannes Berges, Esther Güse, Anja Wessely, Adrian Weich, Jimmy Retzlaff, Jan Dörrie, Niels Schaft, Johannes März, Harald Knorr, Krishna Pal Singh, Elias Andreas Thomas Koch, Nadine D van Kleef, Julian J Freen-van Heeren, Bettina Hohberger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Tumor-associated antigens and their derived peptides constitute an opportunity to design off-the-shelf mainline or adjuvant anti-cancer immunotherapies for a broad array of patients. A performant and rational antigen selection pipeline wou
Externí odkaz:
https://doaj.org/article/f5b73ac9110f43bf9d82c89934e31442
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7275 (2024)
The RNA world is wide, and besides mRNA, there is a variety of other RNA types, such as non-coding (nc)RNAs, which harbor various intracellular regulatory functions. This review focuses on small interfering (si)RNA and micro (mi)RNA, which form a com
Externí odkaz:
https://doaj.org/article/390dd4d881ec49d285effe998e3457fe
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 9, p 4673 (2024)
With the advent of immunotherapeutics, a new era in the combat against cancer has begun. Particularly promising are neo-epitope-targeted therapies as the expression of neo-antigens is tumor-specific. In turn, this allows the selective targeting and k
Externí odkaz:
https://doaj.org/article/158c6ab8a1e24becbdd083b12479ee14
Autor:
Niels Schaft, Jan Dörrie, Gerold Schuler, Beatrice Schuler-Thurner, Husam Sallam, Shiri Klein, Galit Eisenberg, Shoshana Frankenburg, Michal Lotem, Areej Khatib
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The treatment of cancer was revolutionized within the last two decades by utilizing the mechanism of the immune system against malignant tissue in so-called cancer immunotherapy. Two main developments boosted cancer immunotherapy: 1) the use of check
Externí odkaz:
https://doaj.org/article/2d8d1f070bcd4679a5f082af5bcbc7c2
Autor:
Felix Pfister, Jan Dörrie, Niels Schaft, Vera Buchele, Harald Unterweger, Lucas R. Carnell, Patrick Schreier, Rene Stein, Markéta Kubánková, Jochen Guck, Holger Hackstein, Christoph Alexiou, Christina Janko
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundImmunotherapy of cancer is an emerging field with the potential to improve long-term survival. Thus far, adoptive transfer of tumor-specific T cells represents an effective treatment option for tumors of the hematological system such as lym
Externí odkaz:
https://doaj.org/article/46cbcad70ccd47019395acaf9ee98ab1
Publikováno v:
Frontiers in Molecular Medicine, Vol 3 (2023)
Externí odkaz:
https://doaj.org/article/e5126a7dc7bd4bd383c0474bfaf89189
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2022)
Dendritic cells (DCs) can be used for therapeutic vaccination against cancer. The success of this therapy depends on efficient tumor-antigen presentation to cytotoxic T lymphocytes (CTLs) and the induction of durable CTL responses by the DCs. Therefo
Externí odkaz:
https://doaj.org/article/05ea4929ce7049ae8b78e017f0c7525d
Autor:
Elias A. T. Koch, Niels Schaft, Mirko Kummer, Carola Berking, Gerold Schuler, Kenichiro Hasumi, Jan Dörrie, Beatrice Schuler-Thurner
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Uveal melanoma (UM) is an orphan disease with a mortality of 80% within one year upon the development of metastatic disease. UM does hardly respond to chemotherapy and kinase inhibitors and is largely resistant to checkpoint inhibition. Hence, furthe
Externí odkaz:
https://doaj.org/article/6472911da671458fa687e220434108be
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 3, p 2342 (2023)
The development of chimeric antigen receptor T cells (CAR-T cells) has marked a new era in cancer immunotherapy. Based on a multitude of durable complete remissions in patients with hematological malignancies, FDA and EMA approval was issued to sever
Externí odkaz:
https://doaj.org/article/6c61652d0f09430a9dd21c08b798f0b1
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8599 (2022)
Programmed Cell Death 1 Ligand 1 (PD-L1, CD274, B7-H1) is a transmembrane protein which is strongly involved in immune modulation, serving as checkpoint regulator. Interaction with its receptor, Programmed Cell Death Protein 1 (PD-1), induces an immu
Externí odkaz:
https://doaj.org/article/2cc443d3c91840b3beabfc7563f751c0